• We understand what we write

Publications

URL links to publications:

Schmitz S, Hamoir M. Emergency percutaneous tracheotomy. In book: Percutaneous Tracheostomy in Critically Ill Patients, Jan 2016: pp.91-96
http://link.springer.com/chapter/10.1007/978-3-319-22300-1_11

Seront E, Rottey S, Filleul B et al. Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma (TCC). BJU Int 2016; Jan 18. doi: 10.1111/bju.13415. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/26779597

Schmitz S, Duhoux F, Machiels JP. Window of opportunity studies: do they fulfil our expectations? Cancer Treat Rev 2016 Feb;43:50-7. doi: 10.1016/j.ctrv.2015.12.005. Epub 2015 Dec 31.
http://www.ncbi.nlm.nih.gov/pubmed/26827692

Schmitz S, Machiels JP. Targeting the tumour environment in squamous cell carcinoma of the head and neck. Curr Treat Options Oncol 2016 Jul;17(7):37. doi: 10.1007/s11864-016-0412-6.
http://link.springer.com/article/10.1007%2Fs11864-016-0412-6

Dermine A, Machiels JP. Treatment landscape of metastatic prostate cancer: the role of Radium 223. Acta Clin Belg 2016 Jul 4:1-5. [Epub ahead of print] DOI: 10.1080/17843286.2016.1203545.
http://www.tandfonline.com/doi/abs/10.1080/17843286.2016.1203545?journalCode=yacb20

Seront E, Machiels JP. Molecular biology and targeted therapies for urothelial carcinoma. Cancer Treat Rev 2015 Apr;41(4):341-53. doi: 10.1016/j.ctrv.2015.03.004. Epub 2015 Mar 24. 
http://www.cancertreatmentreviews.com/article/S0305-7372(15)00049-3/abstract

Eiszele, A. Improving compliance rates in hand hygiene: The Australian experience. Medical Experts Online 2015.
https://www.medperts.com/region/international/specials-blog/-/blogs/improving-compliance-rates-in-hand-hygiene-the-australian-experience

Schmitz S, Bindea G, Albu RI et al. Cetuximab promotes epithelial to mesenchymal transition and cancer associated fibroblasts in patients with head and neck cancer. Oncotarget 2015 Oct 27;6(33):34288-99. doi: 10.18632/oncotarget.5924
http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=5924&path%5B%5D=14204

Carrasco J, Gizzi M, Pairet G et al. Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone. Br J Cancer 2015; 113: 1298 - 1304.
http://www.nature.com/bjc/journal/v113/n9/full/bjc2015321a.html

Gizzi M, Selda A, Machiels JP. Tubulocystic Carcinoma of the Kidney with Fatal Outcome in an Adolescent Male. Urol Int 2015; 94:485-487
https://www.karger.com/Article/Abstract/366287

Schmitz S, Rommel D, Michoux N et al. Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck. Radiol Oncol 2015 Mar; 49(1): 17 - 25
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362602/

Schmitz S, Hamoir M, Reychler H et al. Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck. Ann Oncol 2013;24(9): 2261-2266 First published online May 23, 2013 doi:10.1093/annonc/mdt180
http://annonc.oxfordjournals.org/content/24/9/2261.abstract

Schmitz S, Ang K, Vermorken J et al. Targeted therapies for squamous cell carcinoma of the head and neck: Current knowledge and future directions. Cancer Treat Rev 2014 Apr;40(3):390-404. doi: 10.1016/j.ctrv.2013.09.007. Epub 2013 Sep 14.
http://www.cancertreatmentreviews.com/article/S0305-7372(13)00196-5/abstract

Schmitz S, Daminsky-Forrett M-C, Henry S., et al. Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02) Ann Oncol 2012;23(8): 2153-2161 First published online January 10, 2012 doi:10.1093/annonc/mdr574
http://annonc.oxfordjournals.org/content/23/8/2153.full.pdf+html

Machiels JP, Mazzeo F, Clausse M et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 2008; 26: 5261-5268
http://jco.ascopubs.org/content/26/32/5261.full.pdf

Personeni N, Fieuws S, Piessevaux H et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab : A fluorescent in situ hybridization study. Clin Cancer Res 2008;14(18): 5869-5876
http://clincancerres.aacrjournals.org/content/14/18/5869.full.pdf

Personeni, N. Outcome prediction to erlotinib in gastroesophageal adenocarcinomas: can we improve epidermal growth factor receptor and phospho-AKT testing? J Clin Oncol 2007; 25: 910
http://jco.ascopubs.org/content/25/7/910.full.pdf

Personeni, N. Epidermal growth factor receptor gene copy number in esophageal cancer and outcome preditction to gefitinib: does intrtumoral heterogeneity matter? J Clin Oncol 2006; 24: 5465
http://jco.ascopubs.org/content/24/34/5465.full.pdf


CONTACT